Regardless of where a drug candidate is in the development pipeline, performing a technology transfer (tech transfer) presents unique challenges for the partners involved.
Overcoming these challenges is critical to ensuring the ultimate success of the product when working with a Contract Development and Manufacturing Organization (CDMO). There are a myriad of ways in which a tech transfer can fail to meet its potential – unsatisfactory yields, unforeseen materials shortages, unoptimized batch sizes that can impact the quality and timelines of the transferred product.
Download our white paper to learn more about the challenges and opportunities of tech transfer, expedited tech transfer through bespoke approaches, choosing a CDMO for your tech transfer, and Emergent's value to partners.
Please complete this form to receive the white paper instantly.